Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma

NCT04782687 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT04782687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04782687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Lead sponsor
US Oncology Research
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 10, 2021
Completion date
May 31, 2026
Enrollment
73 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

kahler disease, multiple myeloma, myeloma multiple, myeloma, plasma cell, myeloma-multiple, myelomatosis, plasma cell myeloma